[AHA 2013] Impact of Chronic Diuretics Therapy on Development of New-onset Diabetes Mellitus in Asian Population

Abstract 12814: Impact of Chronic Diuretics Therapy on Development of New-onset Diabetes Mellitus in Asian Population

Seung Woon Rha; Byoung Geol Choi; Se Yeon Choi; Yoonjee Park; Raghavender Goud Akkala; Sun ki Lee; Ji Bak Kim; Sung Il Im; Jin Oh Na; Cheol Ung Choi; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh

Cardiovascular Cntr, Korea Univ Guro Hosp, Seoul, Korea, Republic of

Background: There have been several reports that diuretics therapy is associated with a higher incidence of new-onset diabetes mellitus (DM). However, there have been limited data whether the chronic diuretic therapy can be a risk factor of new onset DM, especially in Asian population.

Methods: We investigated the 4,231 patients (pts) who had HbA1C level  6.0% and fasting glucose level  100 mg/dL (diuretics group=1,124 and control group=3,107). To adjust potential confounders, a propensity score matched analysis (PSM; diuretics group=954 and control group=954) was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM (HbA1C level > 6.5% or fasting glucose level > 126 mg/dL). Also, multivariable Cox-regression analysis adjusted by aforementioned variables was performed to determine the impact of diuretics therapy on the incidence of new-onset DM.

Results: Mean follow-up duration was 908±558 days in all-pt group, and 982±556 days in PSM group. Baseline characteristics was similar between the two groups. Chronic diuretic therapy in PSM group was not associated with the increased incidence of primary end-point (p=0.204, figure A). However, in cox-regression analysis performed in all pts, diuretics therapy was associated with the increased incidence of primary end-point (figure B).

Conclusions: In our study, chronic diuretics therapy may associated with new-onset DM, but larger, prospective studies are needed to get final conclusion.

Author Disclosures: S. Rha: None. B. Choi: None. S. Choi: None. Y. Park:None. R. Akkala: None. S. Lee: None. J. Kim: None. S. Im: None. J. Na: None.C. Choi: None. H. Lim: None. J. Kim: None. E. Kim: None. C. Park: None. H. Seo: None. D. Oh: None.

Key Words: Type 2 Diabetes